David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Oct

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Verifying the Seen and Unseen by AI in Cancer Imaging

AI-Extracted Chart Data for Expanding Surgical Oncology Learnings

Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families

Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas

Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights